|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Biological half-life||4 hours (healthy adults)
6–7 hours (PKU patients)
|CAS Registry Number|
|Molecular mass||241.25 g/mol|
|(what is this?)|
Tetrahydrobiopterin (BH4, THB, trade name Kuvan) or sapropterin (INN) is a naturally occurring essential cofactor of the three aromatic amino acid hydroxylase enzymes, used in the degradation of amino acid phenylalanine and in the biosynthesis of the neurotransmitters serotonin (5-hydroxytryptamine, 5-HT), melatonin, dopamine, norepinephrine (noradrenaline), epinephrine (adrenaline), and is a cofactor for the production of nitric oxide (NO) by the nitric oxide synthases. Chemically, its structure is that of a reduced pteridine derivative.
Tetrahydrobiopterin is biosynthesized from guanosine triphosphate (GTP) by three chemical reactions mediated by the enzymes GTP cyclohydrolase I (GTPCH), 6-pyruvoyltetrahydropterin synthase (PTPS), and sepiapterin reductase (SR).
Tetrahydrobiopterin has the following responsibilities as a cofactor:
- Tryptophan hydroxylase (TPH) for the conversion of L-tryptophan (TRP) to 5-hydroxytryptophan (5-HTP)
- Phenylalanine hydroxylase (PAH) for conversion of L-phenylalanine (PHE) to L-tyrosine (TYR)
- Tyrosine hydroxylase (TH) for the conversion of L-tyrosine to L-DOPA (DOPA)
- Nitric oxide synthase (NOS) for conversion of a guanidino nitrogen of L-arginine (L-Arg) to nitric oxide (NO)
- Alkylglycerol monooxygenase (AGMO) for the conversion of 1-alkyl-sn-glycerol to 1-hydroxyalkyl-sn-glycerol
Tetrahydrobiopterin has multiple roles in human biochemistry. One is to convert amino acids such as phenylalanine, tyrosine, and tryptophan to precursors of dopamine and serotonin, major monoamine neurotransmitters. Due to its role in the conversion of L-tyrosine into L-dopa, which is the precursor for dopamine, a deficiency in tetrahydrobiopterin can cause severe neurological issues unrelated to a toxic buildup of L-phenylalanine; dopamine is a vital neurotransmitter, and is the precursor of norepinephrine and epinephrine. Thus, a deficiency of BH4 can lead to systemic deficiencies of dopamine, norepinephrine, and epinephrine. In fact, one of the primary conditions that can result from GTPCH-related BH4 deficiency is dopamine-responsive dystonia; currently, this condition is typically treated with carbidopa/levodopa, which directly restores dopamine levels within the brain.
BH4 also serves as a catalyst for the production of nitric oxide. Among other things, nitric oxide is involved in vasodilation, which improves systematic blood flow. The role of BH4 in this enzymatic process is so critical that some research points to a deficiency of BH4 – and thus, of nitric oxide – as being a core cause of the neurovascular dysfunction that is the hallmark of circulation-related diseases such as diabetes.
A deficit in tetrahydrobiopterin biosynthesis and/or regeneration can result in phenylketonuria (PKU) from excess L-phenylalanine concentrations or hyperphenylalaninemia (HPA), as well as monoamine and nitric oxide neurotransmitter deficiency or chemical imbalance. The chronic presence of PKU can result in severe brain damage, including symptoms of mental retardation, microcephaly, speech impediments such as stuttering, slurring, and lisps, seizures or convulsions, and behavioral abnormalities, among other effects.
Tetrahydrobiopterin, developed by BioMarin under the brand name Kuvan and approved by the United States (U.S.) Food and Drug Administration (FDA) on December 13, 2007 and European Medicines Agency (EMA) in 2008, is a synthetic preparation of the dihydrochloride salt of the substance containing ascorbic acid, used in the treatment of PKU and tetrahydrobiopterin deficiencies. Sapropterin is the first non-dietary treatment for patients with PKU that has been shown in randomized, double-blind trials to be effective in lowering blood phenylalanine levels.
Since NO production is important in regulation of blood pressure and blood flow, thereby playing a significant role in cardiovascular diseases, tetrahydrobiopterin is a potential therapeutic target. In the endothelial cell lining of blood vessels, endothelial NOS is dependent on tetrahydrobiopterin availability. Increasing tetrahydrobiopterin in endothelial cells by augmenting the levels of the biosynthetic enzyme GTPCH can maintain endothelial NOS function in experimental models of disease states such as diabetes, atherosclerosis, and hypoxic pulmonary hypertension. However, treatment of patients with existing coronary artery disease with oral tetrahydrobiopterin is limited by oxidation of tetrahydrobiopterin to the inactive form, dihydrobiopterin, with little benefit on vascular function .
Tetrahydrobiopterin may be of benefit in the management and treatment of intractable diastolic heart failure, based on research in mice. There are fewer ways to manage systolic heart failure than for diastolic heart failure.
Other than PKU studies, tetrahydrobiopterin has participated in clinical trials studying other approaches to solving conditions resultant from a deficiency of tetrahydrobiopterin. These include autism, ADHD, hypertension, endothelial dysfunction, and chronic kidney disease. As of September 2010[update], no results are available. Experimental studies suggest that tetrahydrobiopterin regulates deficient production of nitric oxide in cardiovascular disease states, and contributes to the response to inflammation and injury, for example in pain due to nerve injury.
In 1997, a small pilot study was published on the efficacy of tetrahydrobiopterin (BH4) on relieving the symptoms of autism, which concluded that it "might be useful for a subgroup of children with autism" and that double-blind trials are needed, as are trials which measure outcomes over a longer period of time. In 2010, Frye et al. published a paper which concluded that it was safe, and also noted that "several clinical trials have suggested that treatment with BH4 improves ASD symptomatology in some individuals."
The most common adverse effects, observed in more than 10% of patients, include headache and a running or obstructed nose. Diarrhea and vomiting are also relatively common, seen in at least 1% of patients.
No interaction studies have been conducted. Because of its mechanism, tetrahydrobiopterin might interact with dihydrofolate reductase inhibitors like methotrexate and trimethoprim, and NO-enhancing drugs like nitroglycerin, molsidomine, minoxidil, and PDE5 inhibitors. Combination of tetrahydrobiopterin with levodopa can lead to increased excitability.
- Tetrahydrobiopterin deficiency (THBD, BH4D)
- Phenylketonuria (PKU)
- The role of nitric oxide in the hypothalamic control of LHRH and oxytocin release, sexual behavior and aging of the LHRH and oxytocin neurons; FOLIA HISTOCHEMICA ET CYTOBIOLOGICA; Author: Jarosław Całka; Department of Functional Morphology, Division of Animal Anatomy, University of Warmia and Mazury, Olsztyn, Poland; 2005; page 4
- Kaufman, S (1 February 1958). "A New Cofactor Required for the Enzymatic Conversion of Phenylalanine to Tyrosine.". J. Biol. Chem. 230 (2): 931–939. PMID 13525410.
- Thony B, Auerbach G, Blau N (2000). "Tetrahydrobiopterin biosynthesis, regeneration and functions". Biochem J 347 (1): 1–16. doi:10.1042/0264-6021:3470001. PMC 1220924. PMID 10727395.
- "Genetics Home Reference: GCH1". National Institutes of Health.
- Wu, G; Meininger, CJ (2009). "Nitric oxide and vascular insulin resistance". BioFactors (Oxford, England) 35 (1): 21–7. doi:10.1002/biof.3. PMID 19319842.
- Barbara K. Burton, Santwana Kar & Peter Kirkpatrick (2008). "Fresh from the Pipeline: Sapropterin". Nature Reviews Drug Discovery 7 (3): 199–200. doi:10.1038/nrd2540.
- Sanford, Mark; Keating, Gillian M. (2009). "Sapropterin". Drugs 69 (4): 461–76. doi:10.2165/00003495-200969040-00006. PMID 19323589.
- Channon KM. (2004). "Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease". Trends Cardiovasc Med 14 (8): 823–827. doi:10.1016/j.tcm.2004.10.003. PMID 15596110.
- Alp NJ, et al. (2003). "Tetrahydrobiopterin-dependent preservation of nitric oxide–mediated endothelial function in diabetes by targeted transgenic GTP–cyclohydrolase I overexpression". J Clin Invest 112 (5): 725–735. doi:10.1172/JCI17786. PMC 182196. PMID 12952921.
- Khoo J, et al. (2005). "Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension". Circulation 111 (16): 2126–2133. doi:10.1161/01.CIR.0000162470.26840.89. PMID 15824200.
- Cunnington C, et al. (2012). "Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treament in patients with coronary artery disease". Circulation 125 (11): 1356–1366. doi:10.1161/CIRCULATIONAHA.111.038919. PMID 22315282.
- Gad A. Silberman, Tai-Hwang M. Fan, Hong Liu, Zhe Jiao, Hong D. Xiao, Joshua D Lovelock, Beth M. Boulden, Julian Widder, Scott Fredd, Kenneth E. Bernstein, Beata M. Wolska, Sergey Dikalov, David G. Harrison and Samuel C. Dudley, Jr. (2010). "Uncoupled Cardiac Nitric Oxide Synthase Mediates Diastolic Dysfunction". Circulation 121 (4): 519–528. doi:10.1161/CIRCULATIONAHA.109.883777. PMC 2819317. PMID 20083682.
- ClinicalTrials.gov: Search results for Kuvan
- "BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU". BioMarin Pharmaceutical Inc. 17 August 2010.
- Fernell, E.; Watanabe, Y.; Adolfsson, I.; Tani, Y.; Bergström, M.; Phd, P. H.; Md, A. L.; Phd., A. L. V. K. M. .; Phd., C. G. M. .; Phd., B. L. N. M. (2008). "Possible effects of tetrahydrobiopterin treatment in six children with autism - clinical and positron emission tomography data: A pilot study". Developmental Medicine & Child Neurology 39 (5): 313. doi:10.1111/j.1469-8749.1997.tb07437.x.
- Frye, R. E.; Huffman, L. C.; Elliott, G. R. (2010). "Tetrahydrobiopterin as a novel therapeutic intervention for autism". Neurotherapeutics 7 (3): 241–249. doi:10.1016/j.nurt.2010.05.004. PMC 2908599. PMID 20643376.
- Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.